3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Lung Neoplasms
16
Small Cell Lung Carcinoma
10
Breast Neoplasms
8
Esophageal Neoplasms
5
Sarcoma
4
Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Advanced Lung Cancer
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Widespread Small Cell Lung Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Uncommon Pathological Types of Lung Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Lung Cancer
1
Interventions
Carboplatin
24
Pemetrexed
18
Cisplatin
17
Paclitaxel
14
pembrolizumab
13
Gemcitabine
8
osimertinib
7
durvalumab
6
Docetaxel
6
Nivolumab
5
Erlotinib Hydrochloride
5
130-nm albumin-bound paclitaxel
5
capmatinib
3
brigatinib
3
anlotinib
3
Gefitinib
3
Drug Therapy
3
vosaroxin
2
volociximab
2
sintilimab
2
pralsetinib
2
ensartinib
2
atezolizumab
2
aflibercept
2
Surgical Procedures, Operative
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Injections
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled